Kedudukan dalam Saham
#11212
EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating... EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.
Harga Saham
$2.34
Disegerakkan terakhir: 2023-11-09
Perubahan (1 tahun)
0.00%
Perdagangan EQRx, Inc. (EQRX)
Harga EQRX dengan permodalan pasaran b
Modal pasaran bagi EQRx, Inc.(EQRX)
Modal Pasaran: $728.90M
Sehingga August 2026, EQRx, Inc. mempunyai modal pasaran sebanyak $728.90M. Ini menjadikan EQRx, Inc. syarikat ke-11212th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran EQRx, Inc. dari 2021 hingga 2026
EQRX berbanding dengan 5 teratas yang paling popular stocks
| Harga EQRX |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.264T
|
+722,063.20%
|
|
|
|
|
$4.701T
|
+644,879.82%
|
|
|
|
|
$4.177T
|
+572,977.48%
|
|
|
|
|
$3.817T
|
+523,618.82%
|
|
|
|
|
$2.866T
|
+393,139.94%
|
